DDInter1139 DDInter1297
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Niflumic Acid
Niflumic Acid {u} (Compound) resembles {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alpelisib
Alpelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Meclofenamic acid
Meclofenamic acid {u} may lead to a major life threatening interaction when taken with {v} Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Oxybenzone
Oxybenzone {u} (Compound) resembles {v} (Compound) Ketorolac
Ketorolac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Niflumic Acid (Compound) and Niflumic Acid (Compound) resembles Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Niraparib
Mefenamic acid (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Flurbiprofen may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Meclofenamic acid (Compound) and Meclofenamic acid may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Mefenamic acid (Compound) resembles Oxybenzone (Compound) and Oxybenzone (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Niraparib